These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8071685)

  • 21. Pregnancy outcome after treatment with radioiodine for differentiated thyroid carcinoma.
    Balenović A; Vlasić M; Sonicki Z; Bodor D; Kusić Z
    Coll Antropol; 2006 Dec; 30(4):743-8. PubMed ID: 17243543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testicular function after radioiodine therapy in patients with thyroid cancer.
    Rosário PW; Barroso AL; Rezende LL; Padrão EL; Borges MA; Guimarães VC; Purisch S
    Thyroid; 2006 Jul; 16(7):667-70. PubMed ID: 16889490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pregnancy outcome after diagnosis of differentiated thyroid carcinoma: no deleterious effect after radioactive iodine treatment.
    Chow SM; Yau S; Lee SH; Leung WM; Law SC
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):992-1000. PubMed ID: 15234032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of radioiodine treatment for differentiated thyroid cancer on testis function.
    Canale D; Ceccarelli C; Caglieresi C; Moscatelli A; Gavioli S; Santini P; Elisei R; Vitti P
    Clin Endocrinol (Oxf); 2015 Feb; 82(2):295-9. PubMed ID: 25138547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Testicular function after radioiodine therapy for thyroid carcinoma.
    Wichers M; Benz E; Palmedo H; Biersack HJ; Grünwald F; Klingmüller D
    Eur J Nucl Med; 2000 May; 27(5):503-7. PubMed ID: 10853804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.
    Rosário PW; Borges MA; Purisch S
    J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
    Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
    Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testicular dose and fertility in men following I(131) therapy for thyroid cancer.
    Hyer S; Vini L; O'Connell M; Pratt B; Harmer C
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):755-8. PubMed ID: 12072044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma.
    Bourcigaux N; Rubino C; Berthaud I; Toubert ME; Donadille B; Leenhardt L; Petrot-Keller I; Brailly-Tabard S; Fromigué J; de Vathaire F; Simon T; Siffroi JP; Schlumberger M; Bouchard P; Christin-Maitre S
    Hum Reprod; 2018 Aug; 33(8):1408-1416. PubMed ID: 29912343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should we routinely offer a second admission for radioiodine to patients with high-risk differentiated thyroid cancer?
    Gerrard GE; O'Toole L; Roberts F
    Clin Oncol (R Coll Radiol); 2010 Mar; 22(2):136-9. PubMed ID: 20152708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
    Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
    J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma.
    Nakada K; Katoh C; Kanegae K; Tsukamoto E; Shiga T; Mochizuki T; Itoh K; Tamaki N
    J Nucl Med; 1998 May; 39(5):807-10. PubMed ID: 9591580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer.
    Sarkar SD; Beierwaltes WH; Gill SP; Cowley BJ
    J Nucl Med; 1976 Jun; 17(6):460-4. PubMed ID: 944243
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testicular damage after radioactive iodine (I-131) therapy for thyroid cancer.
    Handelsman DJ; Turtle JR
    Clin Endocrinol (Oxf); 1983 May; 18(5):465-72. PubMed ID: 6409459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One size does not fit all: the merit of absorbed doses to the blood in 131I therapy for differentiated thyroid carcinoma.
    Fatholahi L; Tabeie F; Pashazadeh AM; Javadi H; Assadi M; Asli IN
    Health Phys; 2015 Jan; 108(1):53-8. PubMed ID: 25437520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of 131I therapy on peripheral blood in children and adolescents with differentiated thyroid carcinoma].
    Wang J; Zhao W; Liu B; Kuang A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2011 Dec; 28(6):1185-8. PubMed ID: 22295711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma.
    Dottorini ME; Lomuscio G; Mazzucchelli L; Vignati A; Colombo L
    J Nucl Med; 1995 Jan; 36(1):21-7. PubMed ID: 7799075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidative stress in patients with differentiated thyroid cancer: early effects of radioiodine therapy.
    Vrndic OB; Radivojevic SD; Jovanovic MD; Djukic SM; Teodorovic LC; Simonovic ST
    Indian J Biochem Biophys; 2014 Jun; 51(3):223-9. PubMed ID: 25204085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
    Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.